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OBJECTIVE — Subclinical inﬂammation leads to insulin resistance and -cell dysfunction.
This study aimed to assess whether levels of circulating transforming growth factor-1 (TGF-
1)—a central, mainly immunosuppressive, and anti-inﬂammatory cytokine—were associated
with incident type 2 diabetes.
RESEARCH DESIGN AND METHODS — We measured serum levels of TGF-1 from
460 individuals with and 1,474 individuals without incident type 2 diabetes in a prospective
case-cohort study within the population-based MONICA (MONItoring of Trends and Determi-
nants in CArdiovascular Disease)/KORA (Cooperative Health Research in the Region of Augs-
burg) cohort.
RESULTS — ElevatedTGF-1concentrationswereassociatedwithhigher,notlower,riskfor
type 2 diabetes (age-, sex-, and survey-adjusted hazard ratios [95% CI] for increasing TGF-1
tertiles: 1.0, 1.08 [0.83–1.42], and 1.41 [1.08–1.83]; Pfor trend  0.012). Adjustment for BMI
and metabolic and lifestyle factors had virtually no impact on the effect size.
CONCLUSIONS — Elevated serum concentrations of the cytokine TGF-1 indicate an in-
creased risk for type 2 diabetes. TGF-1 may be upregulated to counterbalance metabolic and
immunological disturbances preceding type 2 diabetes.
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S
ubclinical inﬂammation represents
oneimportantmechanisminthede-
velopment of insulin resistance and
-cell dysfunction, and a systemic proin-
ﬂammatory state is associated with in-
creased risk for type 2 diabetes (1).
However, data on anti-inﬂammatory im-
mune mediators are scarce. So far, adi-
ponectin remains the only immune
mediator for which increased circulating
levels indicate a reduced risk for type 2
diabetes and for which a protective effect
is biologically plausible (2–4). Trans-
forming growth factor-1 (TGF-1) is
an interesting candidate in this context
because it is a critical regulator of the
immune system with mainly immuno-
suppressive effects (5). In addition to ef-
fects on T-cells, TGF-1 inhibits or
reverses the activation of macrophages by
interfering with signaling via toll-like re-
ceptor–dependent pathways and down-
regulating central effector mechanisms of
the innate immunity such as lipopolysac-
charide-induced production of proin-
ﬂammatory cytokines, reactive oxygen
species, and reactive nitrogen species
(6,7).
Recent data on interleukin (IL)-1 re-
ceptor antagonist (IL-1Ra) from the
Whitehall II study led to the hypothesis
that the immunological changes before
type 2 diabetes do not only include up-
regulation of proinﬂammatory mediators
butalsoofanti-inﬂammatorycytokines—
presumablyanattempttocounterbalance
subclinical inﬂammation (8). We tested
this hypothesis in the large, population-
based MONICA (MONItoring of Trends
and Determinants in CArdiovascular
Disease)/KORA (Cooperative Health
Research in the Region of Augsburg)
case-cohort study by investigating the as-
sociation between TGF-1 serum levels
and incident type 2 diabetes.
RESEARCH DESIGN AND
METHODS— Data are based on a
prospective case-cohort study within the
population-based MONICA/KORA co-
hort (9–11). This study comprises 1,934
participants (255 men/205 women with
and 724 men/750 women without inci-
dent type 2 diabetes), aged 35–74 years,
from a source population of 7,936 study
participants (supplementary Fig. A1,
available in the online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc09-0476/DC1). Mean  SD follow-up
time was 10.9  4.7 years.
The incidence of type 2 diabetes be-
tween participants’ study start dates and
31 December 2002 was assessed using a
questionnaire sent to all participants of
the three baseline surveys (S1: 1984–
1985, S2: 1989–1990, and S3: 1994–
1995) in 1997–1998 and 2002–2003.
Furthermore, all S1 participants were in-
vitedtoafollow-upexaminationin1987–
1988. Only subjects for whom the
treating physician clearly reported a diag-
nosis of type 2 diabetes or for whom a
diagnosis of type 2 diabetes was men-
tionedinthemedicalrecordsorwhowere
taking antidiabetes medication were clas-
siﬁed as case subjects.
Further information on study design;
collection of demographic, anthropomet-
ric, clinical, metabolic, immunological,
and lifestyle variables; and the statistical
analysis is given in the online appendix.
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the study participants have been de-
scribed for almost identical samples (9–
11). Data for the present sample are given
in supplementary Table A1. Serum con-
centrationsofTGF-1(weightedmean
SE) were 35.8  0.4 ng/ml in case sub-
jects and 35.2  0.2 ng/ml in noncase
subjects (P  0.16). Given that there was
no evidence for interaction between
TGF-1 and sex in the association with
type2diabetes(P0.94intheage-,sex-,
and survey-adjusted model), men and
women were analyzed together.
Case subjects were older than non-
case subjects, and TGF-1 levels were
negatively correlated with age (supple-
mentary Table A2). Adjustment for age
only resulted in hazard ratios (HRs) (95%
CI) for increasing TGF-1 tertiles of 1.0,
1.08 (0.82–1.40), and 1.33 (1.03–1.73)
(Pfor trend  0.024). This association was
slightly stronger when we also adjusted
for sex and survey (model 1, Table 1) and
remainedalmostunchangedwhenwead-
ditionally adjusted for BMI and lifestyle
factors (smoking status, alcohol con-
sumption, and physical activity) in model
2andforsystolicbloodpressure,total-to-
HDL cholesterol ratio, and parental his-
tory of diabetes in model 3. Model 4 also
adjusted for all immune mediators for
which there was some evidence or trend
of correlation with TGF-1( P  0.1; i.e.,
C-reactive protein, macrophage migra-
tion inhibitory factor [MIF], IL-8, soluble
E-selectin, and RANTES [regulated upon
activation, normal T-cell expressed and
secreted]; supplementary Table A3). Al-
though the association was no longer sta-
tistically signiﬁcant, this adjustment left
the effect size almost unaltered.
CONCLUSIONS— Thisstudyfound
that elevated serum concentrations of
TGF-1 are associated with incident type
2diabetes.Theassociationsremainedsta-
bleinmultivariateanalysestakingintoac-
count demographic, anthropometric,
metabolic, and lifestyle factors. Our data
substantiate and extend our recent report
on IL-1Ra and incident type 2 diabetes in
the Whitehall II study (8). Although IL-
1Ra is an anti-inﬂammatory cytokine that
improves metabolic control in patients
with type 2 diabetes (12), we found that
elevated, not decreased, levels of IL-1Ra
preceded the development of type 2 dia-
betes (8). This new ﬁnding underlines
that the immune activation during the
development of type 2 diabetes is com-
plex and includes both pro- and anti-
inﬂammatory mediators. One explanation
could be that elevated concentrations of
TGF-1 and IL-1Ra represent a counter-
regulationoftheproinﬂammatorystatethat
increases the risk for type 2 diabetes.
As an alternative explanation, TGF-1
could also play a proinﬂammatory role in
the development of type 2 diabetes. The
action of TGF-1 depends on the micro-
environment (different leukocyte subsets
andcytokines),andTGF-1canalsopos-
itively regulate immune responses (13).
In the presence of IL-6, TGF-1 supports
the differentiation of T-helper 17 (Th17)
cellsthatareactivatedinmanyproinﬂam-
matoryconditions.Interestingly,IL-6lev-
els were also increased before the onset of
type 2 diabetes in our study (14). Acti-
vated Th17 cells release proinﬂammatory
cytokines such as IL-17 that has been re-
portedtostimulatenitricoxide–mediated
-cell toxicity in a mouse model (15).
The large sample size, the population-
basedstudydesign,andthelongfollow-up
period are strengths of our study. Regard-
ing the limitations, we measured total
TGF-1 after acidiﬁcation of sera and re-
lease of latent TGF-1 instead of biologi-
cally active TGF-1. However, active
TGF-1 has a half-life of 2 min so that its
quantiﬁcation was not feasible.
In conclusion, elevated serum con-
centrations of the mainly immunosup-
pressive cytokine TGF-1 precede the
manifestation of type 2 diabetes. Further
studies are needed to elucidate whether
upregulation of TGF-1 represents an at-
tempt of a protective response against as
yet unrecognized metabolic and immu-
nological disturbances during the devel-
opment of type 2 diabetes or whether
elevated TGF-1 levels in the circulation
may directly contribute to mechanisms
that favor insulin resistance, -cell dys-
function, and type 2 diabetes.
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Table 1—HRs and 95% CIs for the risk of developing type 2 diabetes according to baseline levels of TGF-1
Tertile 1 Tertile 2 Tertile 3 Pfor trend
Median (lower–upper limit) (men) 27.80 (6.10–31.92) 35.17 (31.93–38.44) 43.18 (38.45–60.60)
Median (lower–upper limit) (women) 28.43 (9.17–31.92) 34.75 (31.93–37.63) 42.18 (37.64–59.29)
n of case/noncase subjects 143/481 143/491 174/502
Model 1 1.0 1.08 (0.83–1.42) 1.41 (1.08–1.83)* 0.012
Model 2 1.0 1.09 (0.82–1.46) 1.42 (1.05–1.93)* 0.019
Model 3 1.0 1.09 (0.80–1.48) 1.40 (1.02–1.91)* 0.032
Model 4 1.0 1.02 (0.74–1.42) 1.35 (0.94–1.93) 0.088
DataareHRs(95%CIs)fortertilesofTGF-1(ng/ml)unlessotherwiseindicated.HRsand95%CIswereestimatedbyCoxproportionalhazardsmodels.Modelscontained
continuous variables unless otherwise indicated. Because of the case-cohort design, correction of the variance estimation was performed based on the sampling weights to
give SE estimates for the parameter estimates. The inverse of the sample sizes for the subcohort by the cohort of interest yielded survey- and sex-speciﬁc sampling weights.
If required, we additionally differentiated between case and noncase subjects. Sex-speciﬁc tertiles of the weighted distributions in the subcohort were used. *P  0.05
comparedwithtertile1.Model1:adjustedforage,sex,andsurvey;model2:adjustedforfactorsinmodel1plusBMIandlifestylefactors(i.e.,smokingstatusneversmoker,
formersmoker,andcurrentsmoker,alcoholconsumption0,0.1–39.9,and40g/dayformenand0,0.1–19.9,and20g/dayforwomen,andphysicalactivityinactive
andactive);model3:adjustedforfactorsinmodel2plussystolicbloodpressure,total/HDLcholesterol,andparentalhistoryofdiabetes(negative,positive,andunknown);
model4:adjustedforfactorsinmodel3plusC-reactiveprotein,MIF,IL-8,solubleE-selectin,andRANTES(allincludedinthemodelsstratiﬁedinsex-speciﬁctertiles;sample
size after exclusion of subjects with missing values for additional biomarkers: n  1,847).
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